TYK MEDICINES-B (02410): The first batch of Kadasa (TY-9591) is expected to complete production on November 18.

TYK MEDICINES-B (02410) announces that, as announced by the Company on August 27, 2026, the Company's independently developed new drug Kadasa (TY-9591) has received conditional marketing approval from China's National Medical Products Administration for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations and accompanied by central nervous system (CNS) metastases. The first batch of Kadasa (TY-9591) is expected to complete production on November 18, 2026. The first batch of Kadasa (TY-9591) products is expected to be officially shipped through commercial channels to Qilu's designated first-tier distributors by the end of November 2026. Qilu is expected to launch academic promotion activities on November 13, 2026, marking the official commencement of commercial sales and prescribing of Kadasa (TY-9591) in China. Looking ahead, the Company will continue to collaborate with Qilu Pharmaceutical (Hainan) Co., Ltd. (Qilu) to commercialize Kadasa (TY-9591) in accordance with the license and cooperation agreement and the supply and commercialization agreement as outlined in the Company's announcements dated July 21, 2026 and November 11, 2026.